Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S
Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
Eur Urol. 1995;27(2):104-9. doi: 10.1159/000475138.
A double-blind trial was conducted in 138 patients with superficial transitional cell carcinoma of the bladder following transurethral resection to evaluate the prophylaxis of recurrence by an oral Lactobacillus casei preparation (BLP). Patients were stratified into the following 3 subgroups: (A) with primary multiple tumors; (B) with recurrent single tumors, and (C) with recurrent multiple tumors. In each group, patients were randomly allocated to receive BLP or placebo. BLP showed a better prophylactic effect in subgroups A and B than placebo, whereas no significant difference was observed in subgroup C. Cox multivariate analysis showed that the outcome with BLP was significantly better than with placebo (p = 0.01). Slight and tolerable adverse reactions occurred in 3 patients receiving BLP and in 3 of the placebo-treated patients. Oral administration of BLP was thus safe and effective for preventing recurrence of superficial bladder cancer.
对138例经尿道切除术后的浅表性膀胱移行细胞癌患者进行了一项双盲试验,以评估口服干酪乳杆菌制剂(BLP)预防复发的效果。患者被分为以下3个亚组:(A)原发性多发肿瘤;(B)复发性单发肿瘤;(C)复发性多发肿瘤。在每个亚组中,患者被随机分配接受BLP或安慰剂。BLP在亚组A和B中显示出比安慰剂更好的预防效果,而在亚组C中未观察到显著差异。Cox多因素分析显示,接受BLP治疗的结果明显优于接受安慰剂治疗的结果(p = 0.01)。3例接受BLP治疗的患者和3例接受安慰剂治疗的患者出现了轻微且可耐受的不良反应。因此,口服BLP预防浅表性膀胱癌复发是安全有效的。